Our study suggests that patients expressing high levels of PLOD1 can be targeted for therapies against prolyl 4-hydroxylase alpha subunits pending confirmation that an increase in PLOD1 mRNA results in increases in PLOD1 protein levels in breast cancer patients. Here, PLOD1 is linked to breast cancer.